In vitro and in vivo evaluation of the metabolism and bioavailability of ester prodrugs of MGS0039 (3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3. 1.0]hexane-2,6-dicarboxylic acid), a potent metabotropic glutamate receptor antagonist

Drug Metabolism and Disposition

Volumn 34, Issue 3, 2006, Pages 369-374

  Nakamura, Masato ^a   Kawakita, Yasunori ^a   Yasuhara, Akito ^a   Fukasawa, Yoshiki ^a   Yoshida, Koji ^a   Sakagami, Kazunari ^a   Nakazato, Atsuro ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 3 (3,4 DICHLOROBENZYLOXY) 6 FLUOROBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; ESTER DERIVATIVE; LIVER ENZYME; METABOTROPIC RECEPTOR ANTAGONIST; MGS 0096; MGS 0097; MGS 0103; MGS 0105; MGS 0111; MGS 0112; MGS 0113; MGS 0114; MGS 0115; MGS 0116; MGS 0117; MGS 0144; MGS 0155; MGS 0200; MGS 0201; MGS 0209; MGS 0210; MGS 0211; MGS 0212; MGS 0213; MGS 0215; MGS 0217; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG SCREENING; DRUG TRANSFORMATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BICYCLO COMPOUNDS; BIOLOGICAL AVAILABILITY; DICARBOXYLIC ACIDS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; LIVER; MACACA FASCICULARIS; MALE; PRODRUGS; RECEPTORS, METABOTROPIC GLUTAMATE;

ANIMALIA; MACACA FASCICULARIS;

EID: 33344473087     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.105.006213     Document Type: Article

References (30)

1. Beaumont K, Webster R, Gardner I, and Dack K (2003) Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Curr Drug Metab 4:461-485.
2. Buchwald P and Bodor N (2002) Physicochemical aspects of the enzymatic hydrolysis of carboxylic esters. Pharmazie 57:87-93.
3. Cartmell J, Monn JA, and Schoepp DD (2000) Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine. Psychopharmacology 148:423-429.
4. Chaki S, Yoshikawa R, Hirota S, Shimazak T, Maeda M, Kawashima N, Yoshimizu T, Yasuhara A, Sakagami K, Okuyama S, et al. (2004) MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology 46:457-467.
5. Conn PJ and Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205-237.
6. Cook CS, Karabatsos PJ, Schoenhard GL, and Karim A (1995) Species dependent esterase activities for hydrolysis of an anti-HIV prodrug glycovir and bioavailability of active SC-48334. Pharm Res (NY) 12:1158-1164.
7. Fix JA, Alexander J, Cortese M, Engle K, Leppert P, and Repta AJ (1990) A comparison of oral and rectal absorption of L-dopa esters in rats and mice. Pharm Res (NY) 7:384-387.
8. Grillon C, Cordova J, Levine LR, and Morgan CA 3rd (2003) Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology 168:446-454.
9. Helton DR, Tizzano JP, Monn JA, Schoepp DD, and Kallman MJ (1998) Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J Pharmacol Exp Ther 284:651-660.
10. Inoue M, Morikawa M, Tsuboi M, and Sugiura M (1979) Species difference and characterization of intestinal esterase on the hydrolyzing activity of ester-type drugs. Jpn J Pharmacol 29:9-16.
11. Levine L, Gaydos B, Sheehan D, Goddard A, Feighner J, Potter WZ, and Schoepp DD (2002) The mGluR2/3 receptor antagonist, LY354740, reduces panic anxiety induced by a CO2 challenge in patients diagnosed with panic disorder. Neuropharmacology 43:294-295.
12. Li W, Escarpe PA, Eisenberg EJ, Cundy KC, Sweet C, Jakeman KJ, Merson J, Lew W, Williams M, Zhang L, et al. (1998) Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 42:647-653.
13. Luttrell WE and Castle MC (1988) Species difference in the hydrolysis of meperidine and its inhibition by organophosphate compounds. Fundam Appl Toxicol 11:323-332.
14. Moghaddam B and Adams BW (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science (Wash DC) 281:1349-1352.
15. Monn JA, Valli MJ, Massey SM, Wright RA, Salhoff CR, Johnson BG, Howe T, Alt CA, Rhodes GA, Robey RL, et al. (1997) Design, synthesis, and pharmacological characterization of (+)-2aminobicyclo[3.1.0]hexane-2,6- dicarboxylic acid (LY354740): a potent, selective and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem 40:528-537.
16. Morikawa M, Inoue M, and Tsuboi M (1976) Substrate specificity of carboxylesterase from several animals. Chem Pharm Bull 24:1661-1664.
17. Nakazato A, Kumagai T, Sakagami K, Yoshikawa R, Suzuki Y, Chaki S, Ito H, Taguchi S, Nakanishi S, and Okuyama S (2000) Synthesis, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2, 6-dicarboxylic acid derivatives as potent, selective and orally active group II metabotropic glutamate receptor agonists. J Med Chem 43:4893-4909.
18. Nakazato A, Sakagami K, Yasuhara A, Ohta H, Yoshikawa R, Itoh M, Nakamura M, and Chaki S (2004) Synthesis, in vitro pharmacology, structure-activity relationships and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0] hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists. J Med Chem 47:4570-4587.
19. Ornstein PL, Bleisch TJ, Arnold MB, Kennedy JH, Wright RA, Johnson BG, Tizzano JP, Helton DR, Kallman MJ, Schoepp DD, et al. (1998a) 2-Substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization and bioavailability. J Med Chem 41:358-378.
20. Ornstein PL, Bleisch TJ, Arnold MB, Wright RA, Johnson BG, and Schoepp DD (1998b) 2-Substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl) glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 1. Effects of alkyl, arylalkyl and diarylalkyl substitution. J Med Chem 41:346-357.
21. Parsons CG, Danysz W, and Quack G (1998) Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect 11:523-579.
22. Pin JP and Duvoisin R (1992) The metabotropic glutamate receptors: structure and functions. J Nerochem 58:1184-1186.
23. Prueksaritanont T, Gorham LM, Ellis JD, Fernandez-Metzler C, Deluna P, Gehret JR, Strong KL, Hochman JH, Askew BC, Duggan ME, et al. (1996a) Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studies. Drug Metab Dispos 24:1263-1271.
24. Prueksaritanont T, Gorham LM, Hochman JH, Tran LO, and Vyas KP (1996b) Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines and in Caco-2 cells. Drug Metab Dispos 24:634-642.
25. Quon CY, Mai K, Patil G, and Stampfi HF (1988) Species differences in the stereoselective hydrolysis of esmol by blood esterases. Drug Metab Dispos 16:425-428.
26. Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, and La Du BN (2002) Current progress on esterases: from molecular structure to function. Drug Metab Dispos 30:488-493.
27. Schoepp DD and Conn PJ (1993) Metabotropic glutamate receptors in brain function and pathology. Trends Pharmacol Sci 14:13-20.
28. Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N, Komano T, and Hori R (1992) Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther 263:840-845.
29. Tizzano JP, Griffey KI, and Schoepp DD (2002) The anxiolytic action of mGlu2/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam. Pharmacol Biochem Behav 73:367-374.
30. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Komano T, and Hori R (1992) Human P-glycoprotein transports cortisol, aldosterone and dexamethasone, but not progesterone. J Biol Chem 267:24248-24252.